261 related articles for article (PubMed ID: 30211824)
1. Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model.
Wang Z; Wang M; Hu X; Li Y; Ma D; Li S; Zhao G; Xie Y; Shu Y; Yang J
Transplantation; 2019 Mar; 103(3):502-511. PubMed ID: 30211824
[TBL] [Abstract][Full Text] [Related]
2. Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension.
Helmstädter J; Frenis K; Filippou K; Grill A; Dib M; Kalinovic S; Pawelke F; Kus K; Kröller-Schön S; Oelze M; Chlopicki S; Schuppan D; Wenzel P; Ruf W; Drucker DJ; Münzel T; Daiber A; Steven S
Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):145-158. PubMed ID: 31747801
[TBL] [Abstract][Full Text] [Related]
3. Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.
Gaspari T; Brdar M; Lee HW; Spizzo I; Hu Y; Widdop RE; Simpson RW; Dear AE
Diab Vasc Dis Res; 2016 Jan; 13(1):56-68. PubMed ID: 26408644
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction.
McLean BA; Wong CK; Kabir MG; Drucker DJ
Mol Metab; 2022 Dec; 66():101641. PubMed ID: 36396031
[TBL] [Abstract][Full Text] [Related]
5. The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis.
Li YK; Ma DX; Wang ZM; Hu XF; Li SL; Tian HZ; Wang MJ; Shu YW; Yang J
Pharmacol Res; 2018 May; 131():102-111. PubMed ID: 29530599
[TBL] [Abstract][Full Text] [Related]
6. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
Gaspari T; Liu H; Welungoda I; Hu Y; Widdop RE; Knudsen LB; Simpson RW; Dear AE
Diab Vasc Dis Res; 2011 Apr; 8(2):117-24. PubMed ID: 21562063
[TBL] [Abstract][Full Text] [Related]
7. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
Zhao H; Wang L; Wei R; Xiu D; Tao M; Ke J; Liu Y; Yang J; Hong T
Diabetes Obes Metab; 2014 Sep; 16(9):850-60. PubMed ID: 24641303
[TBL] [Abstract][Full Text] [Related]
8. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.
Baggio LL; Ussher JR; McLean BA; Cao X; Kabir MG; Mulvihill EE; Mighiu AS; Zhang H; Ludwig A; Seeley RJ; Heximer SP; Drucker DJ
Mol Metab; 2017 Nov; 6(11):1339-1349. PubMed ID: 29107282
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet.
Sukumaran V; Tsuchimochi H; Sonobe T; Waddingham MT; Shirai M; Pearson JT
Cardiovasc Diabetol; 2020 Feb; 19(1):24. PubMed ID: 32093680
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update.
Vandemark C; Nguyen J; Zhao ZQ
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771035
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
Jojima T; Uchida K; Akimoto K; Tomotsune T; Yanagi K; Iijima T; Suzuki K; Kasai K; Aso Y
Atherosclerosis; 2017 Jun; 261():44-51. PubMed ID: 28445811
[TBL] [Abstract][Full Text] [Related]
12. Vascular cell adhesion molecule-1 is induced on vascular endothelia and medial smooth muscle cells in experimental cardiac allograft vasculopathy.
Ardehali A; Laks H; Drinkwater DC; Ziv E; Drake TA
Circulation; 1995 Aug; 92(3):450-6. PubMed ID: 7543379
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway.
Liu ZZ; Duan XX; Yuan MC; Yu J; Hu X; Han X; Lan L; Liu BW; Wang Y; Qin JF
Life Sci; 2022 Apr; 294():120370. PubMed ID: 35124000
[TBL] [Abstract][Full Text] [Related]
14. Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer.
Kanda R; Hiraike H; Wada-Hiraike O; Ichinose T; Nagasaka K; Sasajima Y; Ryo E; Fujii T; Osuga Y; Ayabe T
BMC Cancer; 2018 Jun; 18(1):657. PubMed ID: 29907137
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy.
Roumane A; Mcilroy GD; Sommer N; Han W; Heisler LK; Rochford JJ
Front Endocrinol (Lausanne); 2024; 15():1379228. PubMed ID: 38745956
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
[TBL] [Abstract][Full Text] [Related]
17. The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis.
Kushima H; Mori Y; Koshibu M; Hiromura M; Kohashi K; Terasaki M; Fukui T; Hirano T
Cardiovasc Diabetol; 2017 Oct; 16(1):122. PubMed ID: 28969637
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.
Wu X; Li S; Xue P; Li Y
Exp Cell Res; 2017 Nov; 360(2):281-291. PubMed ID: 28919123
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
[TBL] [Abstract][Full Text] [Related]
20. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Noyan-Ashraf MH; Momen MA; Ban K; Sadi AM; Zhou YQ; Riazi AM; Baggio LL; Henkelman RM; Husain M; Drucker DJ
Diabetes; 2009 Apr; 58(4):975-83. PubMed ID: 19151200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
